APOE and Alzheimer disease: We test whether this trajectory modelling approach predicts longitudinal change in cognition and biomarkers (i.e., future tau accumulation) based on baseline non-tau data (Aβ, medial temporal atrophy, APOE 4) over the short timeframes that are typical of AD clinical trials (i.e., 1–3 years) (Fig. 1).